Puma Biotechnology Inc (NYSE:PBYI) Earns “Buy” Rating from Stifel Nicolaus

Puma Biotechnology Inc (NYSE:PBYI)‘s stock had its “buy” rating reiterated by stock analysts at Stifel Nicolaus in a report released on Monday, July 10th. They currently have a $105.00 target price on the biopharmaceutical company’s stock. Stifel Nicolaus’ price target points to a potential upside of 28.91% from the stock’s current price.

Several other brokerages have also commented on PBYI. J P Morgan Chase & Co reissued an “overweight” rating and issued a $89.00 price target on shares of Puma Biotechnology in a report on Wednesday, May 24th. Cowen and Company reissued a “market perform” rating on shares of Puma Biotechnology in a report on Monday, May 22nd. Zacks Investment Research lowered shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Wednesday, June 7th. Credit Suisse Group reissued an “outperform” rating and issued a $58.00 price target on shares of Puma Biotechnology in a report on Tuesday, April 18th. Finally, Leerink Swann reissued an “outperform” rating and issued a $115.00 price target on shares of Puma Biotechnology in a report on Monday, July 10th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $101.75.

Puma Biotechnology (PBYI) traded down 2.63% on Monday, reaching $81.45. 799,832 shares of the company traded hands. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $98.85. The stock’s market capitalization is $3.01 billion. The stock’s 50-day moving average is $88.83 and its 200-day moving average is $54.72.

Puma Biotechnology (NYSE:PBYI) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.09. Equities research analysts expect that Puma Biotechnology will post ($8.43) EPS for the current year.

WARNING: This news story was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.themarketsdaily.com/2017/08/08/puma-biotechnologys-nysepbyi-buy-rating-reaffirmed-at-stifel-nicolaus-updated-updated-updated.html.

In other Puma Biotechnology news, SVP Richard Paul Bryce sold 1,998 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $94.48, for a total value of $188,771.04. Following the transaction, the senior vice president now owns 27,246 shares of the company’s stock, valued at $2,574,202.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of the company’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $75.38, for a total transaction of $93,147,066.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,010,261 shares of company stock worth $159,425,452. Corporate insiders own 22.70% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Strs Ohio bought a new position in Puma Biotechnology during the second quarter worth approximately $122,000. Bank of Montreal Can bought a new position in Puma Biotechnology during the first quarter worth approximately $195,000. Alambic Investment Management L.P. bought a new position in Puma Biotechnology during the first quarter worth approximately $201,000. Teacher Retirement System of Texas bought a new position in Puma Biotechnology during the second quarter worth approximately $211,000. Finally, Fox Run Management L.L.C. bought a new position in Puma Biotechnology during the second quarter worth approximately $227,000. 80.98% of the stock is currently owned by institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply